ipilimumab,nivolumab,cabozantinib
exelixis,bms
['nivo', 'cosmic313']
benefits seen from #cosmic313: early and high rates of disease control (&gt;90%) by adding vegf component
prolonged pfs with cabo-ipi-nivo -- the trial met its primary endpoint
#esmo22 3/n
I treat & research GU cancers @UTSW Dallas. Columbia/Harvard Med/Duke alum; Mom & wife Tweets=my opinions ASCO: https://t.co/Whk29PATXe